Illumina, Inc. — Q3 2015 Form 10-Q Summary
Business context and reporting period
Illumina is a global provider of DNA sequencing and array-based technologies, serving research, clinical, oncology, reproductive health, agriculture, and other applied markets. The filing covers the 13-week quarter and 39-week year-to-date period ended September 27, 2015, compared with the periods ended September 28, 2014. Results are unaudited and prepared under U.S. GAAP.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | YTD 2015 | YTD 2014 |
|---|---|---|---|---|
| Total revenue | $550.3 million | $480.6 million | $1,628.2 million | $1,349.0 million |
| Gross profit | $387.5 million | $333.9 million | $1,138.9 million | $912.8 million |
| Gross margin | 70.4% | 69.5% | 69.9% | 67.7% |
| Income from operations | $140.8 million | $119.5 million | $468.8 million | $311.8 million |
| Net income attributable to Illumina | $118.2 million | $93.5 million | $357.1 million | $200.1 million |
| Diluted EPS | $0.79 | $0.63 | $2.39 | $1.34 |
| Operating cash flow | Not separately provided | Not separately provided | $419.2 million | $360.7 million |
- Q3 revenue increased 14%; year-to-date revenue increased 20.7%.
- Consumables revenue rose 23% in Q3 to $321.1 million and 24% year to date to $932.8 million, driven by growth in the installed sequencing instrument base.
- Q3 instrument revenue declined 3% to $145.4 million, while year-to-date instrument revenue increased 10% to $447.1 million.
- Service and other revenue increased 23% in Q3 and 31% year to date, primarily due to higher NIPT test volumes, genotyping services, and extended instrument service contracts.
- Operating margin was approximately 25.6% in Q3 and 28.8% year to date, compared with 24.9% and 23.1%, respectively, in the prior-year periods.
- Cash and cash equivalents were $551.5 million and short-term investments were $887.9 million at September 27, 2015, for combined liquidity of approximately $1.4 billion.
- Cash flow from operations was $419.2 million; investing cash outflow was $335.5 million, including $107.4 million of capital expenditures; financing cash outflow was $165.6 million. Cash and cash equivalents declined by $84.6 million year to date.
- Debt consisted principally of $104.2 million of 0.25% convertible notes due March 2016, $632.5 million of 0% convertible notes due June 2019, and $517.5 million of 0.5% convertible notes due June 2021. The net carrying amount of convertible-note liabilities was $1.1 billion, including $102.2 million classified as current.
Material changes versus the prior comparable period
- Revenue growth was led by sequencing consumables and services; Q3 instrument shipments, particularly HiSeq X and MiSeq, were lower year over year.
- Gross margin improved due to manufacturing efficiencies, operating leverage, and a favorable mix toward sequencing consumables. Foreign exchange movements were a partial offset.
- Research and development expense increased 17% year to date, and selling, general and administrative expense increased 10%, reflecting higher headcount, scaling investments, and Helix start-up costs.
- Year-to-date net income benefited from a $24.8 million discrete tax benefit related to the exclusion of stock compensation from prior-period cost-sharing charges following a tax court opinion. The company cautioned that a reversal of the opinion could adversely affect future taxes.
- Year-to-date other expense improved versus 2014 because the prior-year period included a $31.4 million loss on extinguishment of debt. In 2015, the company recorded a $3.7 million debt-extinguishment loss and recognized $15.5 million of net cost-method investment gains.
- The company converted $215.9 million of principal of its 2016 convertible notes during the first three quarters, issuing 1.564 million shares for the conversion value above principal.
- Illumina consolidated Helix Holdings I, LLC, a consumer-genomics venture, beginning in July 2015. Helix’s financial statement impact was immaterial, but its redeemable noncontrolling interest was $32.1 million at quarter end.
- The company repurchased approximately 0.4 million shares for $72.2 million year to date. Approximately $208.1 million remained available under existing authorizations at September 27, 2015.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects continued growth in sequencing consumables as the installed base expands. It expects array demand to face migration toward sequencing and lower-complexity, lower-price applications, partly offset by reproductive health, agriculture, and applied-market demand.
- No specific numerical revenue or earnings guidance is provided in the filing. Management stated that cash, cash equivalents, short-term investments, and operating cash flow should fund operating and capital needs for at least the next 12 months.
- Key planned uses of capital include product commercialization, research and development, capital expenditures, facility expansion, strategic acquisitions and investments, share repurchases, and potential cash payments associated with convertible-note conversions.
- The company had $15.0 million of accrued legal contingencies. It stated that litigation outcomes are inherently unpredictable and that losses could exceed recorded accruals and materially affect future results.
- Long-term facility commitments include estimated minimum payments of $204.0 million for a Foster City lease, approximately $147.9 million for a Cambridge-area lease, and $44.1 million of additional payments under a headquarters lease amendment.
- Foreign exchange remains a risk; the company used forward contracts with a total notional amount of approximately $61.3 million at quarter end.
- The company transitioned to a new enterprise resource planning system during Q3 and modified related internal controls. Management concluded that disclosure controls were effective and reported no other material control changes.
- Future performance is subject to technology development and commercialization, manufacturing execution, competition, integration of acquisitions, market demand, taxation, foreign exchange, and legal proceedings. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Whether consumables growth and the expanding sequencing installed base offset weakness or pricing pressure in instruments and arrays.
- The sustainability of the 69.9% year-to-date gross margin after the benefits of favorable mix, manufacturing leverage, and prior-year legal charges.
- The recurring versus nonrecurring components of the 20.9% year-to-date effective tax rate, including the $24.8 million discrete benefit.
- Funding and settlement requirements for the $104.2 million of 2016 convertible notes maturing in March 2016, including potential share issuance or cash conversion payments.
- Potential additional legal losses beyond the $15.0 million accrued contingency and the status of related proceedings.
- Future cash requirements associated with Helix’s contingent put right, lease commitments, capital expenditures, acquisitions, and share repurchases.
- The operational and financial effects of the new ERP implementation and whether related internal controls remain effective in subsequent periods.